Medicamentos de actualidad = Drugs of today

• 

  Año 2017, Vol. 53, Número 8 / Ginés Escolar Albadalejo (aut.), Maribel Díaz Ricart (aut.), Eduardo Arellano Rodrigo (aut.)

  • MONOGRAPHS

    • Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.

      Ginés Escolar Albadalejo, Maribel Díaz Ricart, Eduardo Arellano Rodrigo

      • Resumen

      págs. 423-434

      

    • Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.

      Angelina Passaro, A Prelaj, G. Spitaleri, G. Rossi, A. Del Signore

      • Resumen

      págs. 435-446

      

    • Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.

      Stacey A. Rizza, Vandana Nehra, Zelalem Temesgen

      • Resumen

      págs. 447-452

      

  • INSIGHT

    • Notable licensing deals in the biopharma industry in the second quarter of 2017.

      P D'Souza

      • Resumen

      págs. 456-458

      

  • NEW PRODUCT INTROS

    • New product intros (abaloparatide, deflazacort (new indication), denosumab (new indication), dimethyl fumarate (new indication), dinalbuphine sebacate, glecaprevir/pibrentasvir (new combination), guselkumab, inotuzumab ozogamicin, neratinib, pembrolizumab (new indication), prasterone, sofosbuvir/velpatasvir/voxilaprevir (new combination).

      págs. 459-463